All In Biotech

Drug Trial Radar · NCT05047770

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination

Last checked: Nov 20, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,013 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,013

Actual

Start

Oct 7, 2021

Primary completion

Aug 29, 2022

Study completion Aug 31, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.

Conditions

  • Herpes Zoster

Interventions

  • HZ/suBiological

    2 doses of HZ/su vaccine administered intramuscularly, either sequentially (HZ/suSeq Group) or simultaneously (HZ/suCoAd Group) with the mRNA-1273 booster dose. The second dose of HZ/su was administered 8 weeks after the first dose of HZ/su vaccine.

  • Flu D-QIVCombination product

    1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.

  • mRNA-1273Biological

    1 booster dose of mRNA-1273 vaccine administered intramuscularly at Day 1 (all groups).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-glycoprotein E (gE) Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd Groups, and Between-group RatiosTime frame: At 1 month post-dose 2 of HZ/su vaccine administration (Week 14 for HZ/suSeq group and Week 12 for HZ/suCoAd group)
  2. Anti-S Protein Antibody Concentrations Expressed as GMCs in HZ/suSeq and HZ/suCoAd Groups, and Between-group RatiosTime frame: At 1 month post-mRNA-1273 booster dose administration (Week 4 for both HZ/suSeq and HZ/suCoAd groups)
  3. Anti-hemagglutinin Inhibition (HI) Antibody Titers Expressed as Geometric Mean Titers (GMTs) Against the 4 Influenza Strains in Flu D-QIV Vaccine in FluD-QIVSeq and FluD-QIVCoAd Groups, and Between-group RatiosTime frame: At 1 month post-Flu D-QIV vaccine dose administration (Week 6 for FluD-QIVSeq group and Week 4 for FluD-QIVCoAd group)
  4. Anti-S Protein Antibody Concentrations Expressed as GMCs in FluD-QIVSeq and FluD-QIVCoAd Groups, and Between-group RatiosTime frame: At 1 month post-mRNA-1273 booster dose administration (Week 4 for both FluD-QIVSeq and FluD-QIVCoAd groups)

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tempe, Arizona

  • GSK Investigational Site

    Oxnard, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Atlantis, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Ocala, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Meridian, Idaho

  • GSK Investigational Site

    El Dorado, Kansas

  • GSK Investigational Site

    Newton, Kansas

  • GSK Investigational Site

    Topeka, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Biloxi, Mississippi

  • GSK Investigational Site

    Fremont, Nebraska

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Berlin, New Jersey

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Norman, Oklahoma

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Yukon, Oklahoma

  • GSK Investigational Site

    Grants Pass, Oregon

  • GSK Investigational Site

    Anderson, South Carolina

  • GSK Investigational Site

    Columbia, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Memphis, Tennessee

  • GSK Investigational Site

    Beaumont, Texas

  • GSK Investigational Site

    Cedar Park, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    San Antonio, Texas

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.